Rocket Pharmaceuticals to Present at March 2026 Investor Conferences

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference and Leerink Partners Global Healthcare Conference in Boston and Miami, respectively.

The Chief Executive Officer will take part in a fireside chat and management will host investor meetings at each conference. The TD Cowen 46th Annual Health Care Conference is scheduled for March 2, 2026 at 11:10 AM ET. The Leerink Partners Global Healthcare Conference is scheduled for March 10, 2026 at 9:20 AM ET.

Webcasts of the presentations will be available on the Investors section of the Company's website.

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders.

Rocket's adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage clinical program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, and an early-stage clinical program for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death. Rocket has also received IND clearance for its AAV-based gene therapy for BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles.

Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia.